22 results
Thumbnail

D2.471 - Efficacy of omalizumab in the treatment of chronic spontaneous urticaria in children

Thumbnail

D2.473 - Omalizumab as adjuvant therapy in drug desensitization to chemotherapy- a single Center experience

Thumbnail

D2.475 - Treatment delay and likelihood of remission on omalizumab in chronic spontaneous urticaria: a real-world observational study

Thumbnail

D2.464 - Stapokibart (anti–IL-4Rα monoclonal antibody) across type 2 inflammatory diseases in routine practice: a three-case series of severe atopic dermatitis, chronic urticaria with rhinosinusitis, and immune-related bullous pemphigoid

Thumbnail

D2.465 - Omalizumab Enhances Safety and Supports Completion of Oral Immunotherapy in High-Risk Patients

Thumbnail

D2.466 - More options for the treatment of Chronic Spontaneous Urticaria: Tezepelumab

Thumbnail

D2.467 - Management of Netherton syndrome and hereditary angioedema with concurrent biologic therapy: a novel case

Thumbnail

D2.468 - Real-world effectiveness and safety of dupilumab in pediatric atopic dermatitis: a retrospective cohort study

Thumbnail

D2.469 - Pre-switch perceptions of omalizumab biosimilar prefilled pen in pediatric allergy: a cross-sectional survey

Thumbnail

D2.470 - Potential Clinical and Laboratory Biomarkers for Predicting Omalizumab Response in Chronic Spontaneous Urticaria

Thumbnail

D2.472 - Immunology Innovation Program: Developing Antibodies Against Novel Targets Through Co-creation

Thumbnail

D2.474 - Use of Dupilumab as treatment for Eosinophilic Enteritis: a case report

Thumbnail

D2.476 - Mepolizumab Enables Meaningful Real-World Improvements in SNOT-22 and Smell Dysfunction in Chronic Rhinosinusitis with Nasal Polyps: Post Hoc Analysis of REALITI-N at 3 and 6 Months

Thumbnail

D3.166 - Attention-deficit/hyperactivity disorder (ADHD) in asthmatic children

Thumbnail

D3.168 - Clinical Department of Allergy Center in Linköping

Thumbnail

D3.169 - Paediatric Severe Acute Respiratory Infections in Malta: A Three-Year Review

Thumbnail

D3.171 - Validation of the Kazakh Version of the Asthma Quality of Life Questionnaire (AQLQ) for Clinical Use in Adult Patients with Asthma

Thumbnail

D3.173 - Switching from Dupilumab to Tezepelumab in a Child with Severe Asthma and Atopic Dermatitis: Clinical Considerations and Therapeutic Implications

Thumbnail

D3.174 - Short-term tolerance of omlyclo, the omalizumab biosimilar

Thumbnail

D3.175 - Algorithm for Biologics Selection in Severe Asthma